Patent: 9,260,721
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,260,721
| Title: | Expression vector and methods of producing high levels of proteins |
| Abstract: | A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or a functional variant thereof, b) an intron, c) TPL or a functional variant thereof, d) VA gene or a functional variant thereof, and e) a bovine growth hormone polyadenylation sequence or a functional variant thereof. |
| Inventor(s): | Singh; Arun K. (Gujarat, IN), Goel; Ashish (Gujarat, IN), Mendiratta; Sanjeev K. (Gujarat, IN) |
| Assignee: | Cadila Healthcare Limited (Ahmedabad, IN) |
| Application Number: | 13/471,501 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,260,721
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | See Plans and Pricing | 2025-06-20 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | See Plans and Pricing | 2025-06-20 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | See Plans and Pricing | 2025-06-20 | |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2025-06-20 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | See Plans and Pricing | 2025-06-20 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2025-06-20 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2025-06-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
